ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$18.33 USD
-0.86 (-4.48%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $18.22 -0.11 (-0.60%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for ArriVent BioPharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 150 | 163 | 37 | -99,999 | -99,999 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 10 | 19 | 6 | NA | NA |
Total Current Assets | 160 | 183 | 43 | NA | NA |
Net Property & Equipment | 0 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 3 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 163 | 183 | 43 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 5 | 3 | 0 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 7 | 5 | 2 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 0 | 0 | NA | NA |
Total Current Liabilities | 12 | 8 | 2 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 12 | 8 | 2 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 304 | 260 | 90 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 5 | 3 | 3 | NA | NA |
Retained Earnings | -158 | -89 | -52 | NA | NA |
Other Equity | 0 | 0 | 0 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 151 | 174 | 41 | NA | NA |
Total Liabilities & Shareholder's Equity | 163 | 183 | 43 | NA | NA |
Total Common Equity | -153 | -85 | -49 | 0 | 0 |
Shares Outstanding | 31.90 | NA | NA | NA | NA |
Book Value Per Share | -4.80 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for ArriVent BioPharma, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 317 | 150 | -99,999 | -99,999 | 0 |
Receivables | 0 | 0 | NA | NA | 0 |
Notes Receivable | 0 | 0 | NA | NA | 0 |
Inventories | 0 | 0 | NA | NA | 0 |
Other Current Assets | 10 | 10 | NA | NA | 0 |
Total Current Assets | 327 | 160 | NA | NA | 0 |
Net Property & Equipment | 0 | 0 | NA | NA | 0 |
Investments & Advances | 0 | 0 | NA | NA | 0 |
Other Non-Current Assets | 0 | 0 | NA | NA | 0 |
Deferred Charges | 0 | 3 | NA | NA | 0 |
Intangibles | 0 | 0 | NA | NA | 0 |
Deposits & Other Assets | 0 | 0 | NA | NA | 0 |
Total Assets | 328 | 163 | NA | NA | 0 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | 0 |
Accounts Payable | 4 | 5 | NA | NA | 0 |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | 0 |
Current Portion Capital Leases | 0 | 0 | NA | NA | 0 |
Accrued Expenses | 6 | 7 | NA | NA | 0 |
Income Taxes Payable | 0 | 0 | NA | NA | 0 |
Other Current Liabilities | 0 | 0 | NA | NA | 0 |
Total Current Liabilities | 10 | 12 | NA | NA | 0 |
Mortgages | 0 | 0 | NA | NA | 0 |
Deferred Taxes/Income | 0 | 0 | NA | NA | 0 |
Convertible Debt | 0 | 0 | NA | NA | 0 |
Long-Term Debt | 0 | 0 | NA | NA | 0 |
Non-Current Capital Leases | 0 | 0 | NA | NA | 0 |
Other Non-Current Liabilities | 0 | NA | NA | 0 | |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | 0 |
Total Liabilities | 10 | 12 | NA | NA | 0 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 304 | NA | NA | 0 |
Common Stock (Par) | 0 | 0 | NA | NA | 0 |
Capital Surplus | 493 | 5 | NA | NA | 0 |
Retained Earnings | -175 | -158 | NA | NA | 0 |
Other Equity | 0 | 0 | NA | NA | 0 |
Treasury Stock | 0 | 0 | NA | NA | 0 |
Total Shareholder's Equity | 318 | 151 | NA | NA | 0 |
Total Liabilities & Shareholder's Equity | 328 | 163 | NA | NA | 0 |
Total Common Equity | 318 | -153 | 0 | 0 | 0 |
Shares Outstanding | 33.40 | 31.90 | NA | NA | NA |
Book Value Per Share | 9.51 | -4.80 | 0.00 | 0.00 | 0.00 |